Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Autosomal recessive diseases, such as cystic fibrosis (CF), require inheritance of 2 mutated genes. However, some studies indicate that CF carriers are at increased risk for some conditions associated with CF. These investigations focused on single conditions and included small numbers of subjects. Our goal was to determine whether CF carriers are at increased risk for a range of CF-related conditions. Using the Truven Health MarketScan Commercial Claims database (2001–2017), we performed a population-based retrospective matched-cohort study. We identified 19,802 CF carriers and matched each carrier with 5 controls. The prevalence of 59 CF-related diagnostic conditions was evaluated in each cohort. Odds ratios for each condition were computed for CF carriers relative to controls. All 59 CF-related conditions were more prevalent among carriers compared with controls, with significantly increased risk ( P < 0.05) for 57 conditions. Risk was increased for some conditions previously linked to CF carriers (e.g., pancreatitis, male infertility, bronchiectasis), as well as some conditions not previously reported (e.g., diabetes, constipation, cholelithiasis, short stature, failure to thrive). We compared our results with 23,557 subjects with CF, who were also matched with controls; as the relative odds of a given condition increased among subjects with CF, so did the corresponding relative odds for carriers ( P < 0.001). Although individual-level risk remained low for most conditions, because there are more than 10 million carriers in the US, population-level morbidity attributable to the CF carrier state is likely substantial. Genetic testing may inform prevention, diagnosis, and treatment for a broad range of CF carrier-related conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Webb, A. K. (2006) · Cited by 4,369
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228 · cited 1×
“For example, the CFTR potentiator ivacaftor increases the open-state probability of wild-type CFTR (42, 43), and its Table 2.”
Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032 · cited 1×
“However, most CF carriers (∼70% in the US) have the F508del mutation (44, 45).”
Cystic fibrosis genetics: from molecular understanding to clinical application
Cutting, G. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3849 · Cited by 965
Mutations of the Cystic Fibrosis Gene in Patients with Chronic Pancreatitis
Sharer, N., Schwarz, M., Malone, G., Howarth, A., Painter, J., Super, M., & Braganza, J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809033391001 · Cited by 954 · cited 2×
“…found a higher-than-expected proportion of CF carriers with a limited number of CF-related conditions, including congenital bilateral absence of vas deferens (14, 15), sinusitis (16 – 18), pancreatitis (19 – 21), bronchiectasis (22 – 24), mycobacterial infections (25 – 27), and asthma (23, 28).”
Mutations in the Cystic Fibrosis Gene in Patients with Congenital Absence of the Vas Deferens
Chillón, M., Casals, T., Mercier, B., Bassas, L., Lissens, W., Silber, S., Romey, M.-C., Ruiz-Romero, J., Verlingue, C., Claustres, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322204 · Cited by 952 · cited 2×
“Previous investigators have reported that CF carriers are at increased risk for some the conditions we reported, including infertility (14, 15), pancreatitis (19–21), and sinopulmonary infections (16–18, 25–27, 29, 30).”
Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung
Pezzulo, A. A., Tang, X. X., Hoegger, M. J., Abou Alaiwa, M. H., Ramachandran, S., Moninger, T. O., Karp, P. H., Wohlford-Lenane, C. L., Haagsman, H. P., van Eijk, M., et al. (2012) · Nature · doi:10.1038/nature11130 · Cited by 808
Self-citationOrigins of Cystic Fibrosis Lung Disease
Stoltz, D. A., Meyerholz, D. K., & Welsh, M. J. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300109 · Cited by 669 · cited 1×
“Decreased HCO 3 − secretion and an abnormally acidic airway surface liquid may contribute to lung disease in people with CF (3, 39 – 41) and may explain the elevated risk of lung disease that we found for carriers.”
Self-citationWatson, M. S., Cutting, G. R., Desnick, R. J., Driscoll, D. A., Klinger, K., Mennuti, M., Palomaki, G. E., Popovich, B. W., Pratt, V. M., Rohlfs, E. M., et al. (2004) · Genetics in Medicine · doi:10.1097/01.gim.0000139506.11694.7c · Cited by 470 · cited 1×
“However, most CF carriers (∼70% in the US) have the F508del mutation (44, 45).”
Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis
Johnson, L. G., Olsen, J. C., Sarkadi, B., Moore, K. L., Swanstrom, R., & Boucher, R. C. (1992) · Nature Genetics · doi:10.1038/ng0992-21 · Cited by 439 · cited 1×
“In airway epithelia, Cl − secretion by carriers does not differ from that of controls (32); however, a rate-limiting step for Cl − secretion by airway epithelia is Cl − entry across the basolateral membrane and not exit through apical CFTR (32, 36 – 38).”
Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study
McKone, E. F., Emerson, S. S., Edwards, K. L., & Aitken, M. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13368-5 · Cited by 397 · cited 1×
“The clinical manifestations and severity of CF vary (1, 4 – 6), but gene mutations producing lower levels of functional CFTR are generally associated with more severe disease (6 – 8).”
Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis
Quinton, P. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61162-9 · Cited by 381 · cited 1×
“Decreased HCO 3 − secretion and an abnormally acidic airway surface liquid may contribute to lung disease in people with CF (3, 39 – 41) and may explain the elevated risk of lung disease that we found for carriers.”
Wang, X. (2000) · JAMA · doi:10.1001/jama.284.14.1814 · Cited by 270
Cystic fibrosis: a clinical view
Castellani, C., & Assael, B. M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2393-9 · Cited by 254 · cited 2×
“Thus, CF carriers, having only 1 defective CFTR gene, are not considered to be at increased risk for CF-related conditions (9, 10), and CF carriers are routinely informed that they are not at increased health risk (11–13).”
Wilschanski, M., Zielenski, J., Markiewicz, D., Tsui, L.-C., Corey, M., Levison, H., & Durie, P. R. (1995) · The Journal of Pediatrics · doi:10.1016/s0022-3476(95)70157-5 · Cited by 235 · cited 1×
“The clinical manifestations and severity of CF vary (1, 4 – 6), but gene mutations producing lower levels of functional CFTR are generally associated with more severe disease (6 – 8).”
Yu, J., Chen, Z., Ni, Y., & Li, Z. (2012) · Human Reproduction · doi:10.1093/humrep/der377 · Cited by 233 · cited 2×
“Previous investigators have reported that CF carriers are at increased risk for some the conditions we reported, including infertility (14, 15), pancreatitis (19–21), and sinopulmonary infections (16–18, 25–27, 29, 30).”
Trapnell, B. C., Chu, C. S., Paakko, P. K., Banks, T. C., Yoshimura, K., Ferrans, V. J., Chernick, M. S., & Crystal, R. G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6565 · Cited by 232 · cited 1×
“What is the physiological basis for the increased risk of CFrelated conditions in carriers? Carriers have ∼50% as much CFTR anion channel activity as controls (31, 32), and in some epithelia, anion transport is known to be reduced in carriers.”
CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis
McKone, E. F., Goss, C. H., & Aitken, M. L. (2006) · Chest · doi:10.1378/chest.130.5.1441 · Cited by 202
Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders
Moskowitz, S. M., Chmiel, J. F., Sternen, D. L., Cheng, E., Gibson, R. L., Marshall, S. G., & Cutting, G. R. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31818e55a2 · Cited by 184
CFTR Gene Mutations in Adults with Disseminated Bronchiectasis
Girodon, E., Cazeneuve, C., Lebargy, F., Chinet, T., Costes, B., Ghanem, N., Martin, J., Lemay, S., Scheid, P., HOUSSET, B., et al. (1997) · European Journal of Human Genetics · doi:10.1159/000484750 · Cited by 178
Análisis farmacoeconómico de la pentoxifilina en úlceras venosas
Marinel·lo-Roura, J., Iglesias-García, C., Lorenzo-Ferrer, J., Mercadal-Dalmau, J., & Lozano-Fernández de Pinedo, R. (2007) · Angiología · doi:10.1016/s0003-3170(07)75026-5 · Cited by 174
Control of CFTR chloride conductance by ATP levels through non-hydrolytic binding
Quinton, P. M., & Reddy, M. M. (1992) · Nature · doi:10.1038/360079a0 · Cited by 168
Weiss, F. U., Simon, P., Bogdanova, N., Mayerle, J., Dworniczak, B., Horst, J., & Lerch, M. M. (2005) · Gut · doi:10.1136/gut.2005.064808 · Cited by 159 · cited 2×
“…found a higher-than-expected proportion of CF carriers with a limited number of CF-related conditions, including congenital bilateral absence of vas deferens (14, 15), sinusitis (16 – 18), pancreatitis (19 – 21), bronchiectasis (22 – 24), mycobacterial infections (25 – 27), and asthma (23, 28).”
Increasing nontuberculous mycobacteria infection in cystic fibrosis
Bar-On, O., Mussaffi, H., Mei‐Zahav, M., Prais, D., Steuer, G., Stafler, P., Hananya, S., & Blau, H. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.05.008 · Cited by 145 · cited 2×
“…found a higher-than-expected proportion of CF carriers with a limited number of CF-related conditions, including congenital bilateral absence of vas deferens (14, 15), sinusitis (16 – 18), pancreatitis (19 – 21), bronchiectasis (22 – 24), mycobacterial infections (25 – 27), and asthma (23, 28).”
Increased Prevalence of Chronic Rhinosinusitis in Carriers of a Cystic Fibrosis Mutation
Wang, X., Kim, J., McWilliams, R. M., & Cutting, G. R. (2005) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.131.3.237 · Cited by 141 · cited 1×
“Previous investigators have reported that CF carriers are at increased risk for some the conditions we reported, including infertility (14, 15), pancreatitis (19 – 21), and sinopulmonary infections (16 – 18, 25 – 27, 29, 30).”
Farmen, S. L., Karp, P. H., Ng, P., Palmer, D. J., Koehler, D. R., Hu, J., Beaudet, A. L., Zabner, J., & Welsh, M. J. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00049.2005 · Cited by 139
Self-citationSweat Chloride Concentrations in Infants Homozygous or Heterozygous for F508 Cystic Fibrosis
Farrell, P. M., & Koscik, R. E. (1996) · PEDIATRICS · doi:10.1542/peds.97.4.524 · Cited by 129 · cited 1×
“Another example is that carriers have pilocarpinestimulated sweat Cl concentrations that lie between control and CF values (35); sweat Cl concentration depends on CFTRmediated Cl absorption by epithelia in the sweat gland duct.”
Ziedalski, T. M., Kao, P. N., Henig, N. R., Jacobs, S. S., & Ruoss, S. J. (2006) · CHEST Journal · doi:10.1378/chest.130.4.995 · Cited by 126
Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers
Cohn, J. A., Neoptolemos, J. P., Feng, J., Yan, J., Jiang, Z., Greenhalf, W., McFaul, C., Mountford, R., & Sommer, S. S. (2005) · Human Mutation · doi:10.1002/humu.20232 · Cited by 116
Raman, V. T., Clary, R. A., Siegrist, K. L., Zehnbauer, B. A., & Chatila, T. A. (2002) · PEDIATRICS · doi:10.1542/peds.109.1.e13 · Cited by 100 · cited 2×
“…found a higher-than-expected proportion of CF carriers with a limited number of CF-related conditions, including congenital bilateral absence of vas deferens (14, 15), sinusitis (16 – 18), pancreatitis (19 – 21), bronchiectasis (22 – 24), mycobacterial infections (25 – 27), and asthma (23, 28).”
Zabner, J., Couture, L. A., Smith, A. E., & Welsh, M. J. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.5-585 · Cited by 91
Self-citationShah, V. S., Ernst, S. E., Tang, X. X., Karp, P. H., Parker, C. P., Ostedgaard, L. S., & Welsh, M. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604905113 · Cited by 88 · cited 2×
“In airway epithelia, Cl secretion by carriers does not differ from that of controls (32); however, a rate-limiting step for Cl secretion by airway epithelia is Cl entry across the basolateral membrane and not exit through apical CFTR (32, 36–38).”
BackgroundSelf-citationBronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations?
Casals, T., de Gracia, J., Gallego, M., Dorca, J., Rodriguez-Sanchon, B., Ramos, M., Giménez, J., Cisteró‐Bahíma, A., Olveira, C., & Estivill, X. (2004) · Clinical Genetics · doi:10.1111/j.0009-9163.2004.00265.x · Cited by 87 · cited 1×
“…found a higher-than-expected proportion of CF carriers with a limited number of CF-related conditions, including congenital bilateral absence of vas deferens (14, 15), sinusitis (16 – 18), pancreatitis (19 – 21), bronchiectasis (22 – 24), mycobacterial infections (25 – 27), and asthma (23, 28).”
Familial Clustering of Pulmonary Nontuberculous Mycobacterial Disease
Colombo, R. E., Hill, S. C., Claypool, R. J., Holland, S. M., & Olivier, K. N. (2009) · CHEST Journal · doi:10.1378/chest.09-1173 · Cited by 81 · cited 2×
“…found a higher-than-expected proportion of CF carriers with a limited number of CF-related conditions, including congenital bilateral absence of vas deferens (14, 15), sinusitis (16 – 18), pancreatitis (19 – 21), bronchiectasis (22 – 24), mycobacterial infections (25 – 27), and asthma (23, 28).”
Cook, D. P., Rector, M. V., Bouzek, D. C., Michalski, A. S., Gansemer, N. D., Reznikov, L. R., Li, X., Stroik, M. R., Ostedgaard, L. S., Alaiwa, M. H. A., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1562oc · Cited by 70 · cited 1×
“For example, the CFTR potentiator ivacaftor increases the open-state probability of wild-type CFTR (42, 43), and its Table 2.”
Self-citationHealthcare expenditures for privately insured US patients with cystic fibrosis, 2010‐2016
Grosse, S. D., Do, T. Q. N., Vu, M., Feng, L. B., Berry, J. G., & Sawicki, G. S. (2018) · Pediatric Pulmonology · doi:10.1002/ppul.24178 · Cited by 51
Risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis
Nielsen, A. O., Qayum, S., Bouchelouche, P. N., et al. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2016.06.001 · Cited by 35 · cited 1×
“However, some studies have found a higher-than-expected proportion of CF carriers with a limited number of CF-related conditions, including congenital bilateral absence of vas deferens (14, 15), sinusitis (16–18), pancreatitis (19–21), bronchiectasis (22–24), mycobacterial infections (25–27), and asthma (23, 28).”
Variable reduction in beta-adrenergic sweat secretion in cystic fibrosis heterozygotes.
Sato, K., & Sato, F. (1988) · PubMed · Cited by 31
CFTR Heterozygotes Are at Increased Risk of Respiratory Infections: A Population-Based Study
Polgreen, P. M., Brown, G., Hornick, D. B., Ahmad, F., London, B., Stoltz, D. A., & Comellas, A. P. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy219 · Cited by 30 · cited 1×
“Previous investigators have reported that CF carriers are at increased risk for some the conditions we reported, including infertility (14, 15), pancreatitis (19 – 21), and sinopulmonary infections (16 – 18, 25 – 27, 29, 30).”
Self-citationFerril, G. R., Nick, J. A., Getz, A. E., Barham, H. P., Saavedra, M. T., Taylor‐Cousar, J. L., Nichols, D. P., Curran‐Everett, D., Kingdom, T. T., & Ramakrishnan, V. R. (2014) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21412 · Cited by 26 · cited 1×
“The clinical manifestations and severity of CF vary (1, 4 – 6), but gene mutations producing lower levels of functional CFTR are generally associated with more severe disease (6 – 8).”
Cited by
Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32542-3 · Cited by 682
Putman, M. S., Norris, A. W., Hull, R. L., Rickels, M. R., Sussel, L., Blackman, S. M., Chan, C. L., Ode, K. L., Daley, T., Stecenko, A. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0380 · Cited by 35
“dence of association with CFRD risk (26,27).”
Metadata
- Authors
- Miller, A. C., Comellas, A. P., Hornick, D. B., Stoltz, D. A., Cavanaugh, J. E., Gerke, A. K., Welsh, M. J., Zabner, J., & Polgreen, P. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2019-12-27
- Volume
- 117
- Issue
- 3
- Pages
- 1621-1627
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2997710838
- Cited by
- 196
- References
- 41
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.